Stanford Medicine researchers have built CRISPR-GPT, a large language model designed to automate the full arc of gene-editing ...

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

CRISPR promises revolutionary cures, but its edits aren’t always perfect. To tackle hidden risks, UC San Diego researchers developed the ICP system, which fingerprints genetic edits and shows how they ...

Researchers have built a series of CRISPR-based platforms that can switch endogenous genes on and, just as critically, dial ...

A Swiss biotechnology company said it has used the gene-editing technology CRISPR to treat a patient with a dangerous blood disease called beta thalassemia, marking the technology’s first trial run by ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

CRISPR Therapeutics (CRSP) is back in focus after upsizing its convertible note offering to US$550 million, a key funding move tied directly to the company’s gene editing ambitions and CASGEVY ...

CRISPR Therapeutics CRSP and Intellia Therapeutics NTLA are leading developers of therapies that utilize the Nobel Prize-winning CRISPR/Cas9 gene editing technology. While CRSP is the first and only ...

UC San Diego researchers have created a new system that reveals specific categories of potentially risky mutations resulting from CRISPR edits. This high magnification image reveals CRISPR-based DNA ...